The Priority Review

Clinical trials Brief

Keymed registers Phase 3 trial of CM336+CM313 in relapsed multiple myeloma

The study, led by Keymed Biosciences Co.Ltd, plans to enroll 320 participants and start in December 2026. It compares CM336+CM313 with Daratumumab+Pomalidomide+Dexamethasone in patients who have received 1 to 3 prior lines of therapy.

Primary source

ClinicalTrials.gov registry record, November 2, 2026

Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Read the source clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation